Member Info for daveycaferacer

This is a great opening, currently now $78 (around £7.00). I have been hoping for a long time that the Company would list in HK and the listing would be well received. At last it seems our valuation may become more aligned with other companies of a similar type and size.

Join us for the live streaming of HUTCHMED's HKEX Listing Ceremony on 30 Jun 9am HKT ( 9pm EDT, 29 Jun ) ! We will trade under the stock code "13" in Hong Kong

https://www.livestudio.one/en/event/video/HKEXListingCeremony

I'll certainly be there!!

https://www.fiercepharma.com/pharma/other-drugs-are-approved-for-it-us-but-az-and-hutchmed-get-first-nod-china-for-rare-type

BeiGene won approval Monday for its 200 billion yuan ($31 billion) initial public offering (IPO) on the Shanghai Stock Exchange’s Nasdaq-like STAR Market, making it the first Chinese biopharmaceutical company to have shares listed on the Chinese mainland, in Hong Kong and in the U.S

Could HUTCHMED be next?

Innovent has a similar size pipeline, is loss making and similar revs to our forecast 2022 revs, yet it has a P/S of 35. I expect Hutchmed to get to a similar multiple of revenues prior to being profitable. HK and Chinese Investors seem very supportive of Biopharma Co's and will value the Company accordingly in my view.

"I spoke to GC in the AGM AND HE SAID THERE WILL BE A PRESS RELEASE in 14 days about Accustem hope this makes people feel abit better"

With his track record on Corporate timings no, it doesn't.

"I spoke to GC in the AGM AND HE SAID THERE WILL BE A PRESS RELEASE in 14 days about Accustem hope this makes people feel abit better"

Well, his track record on timing is abysmal so it could be 14 weeks or 14 months

thx for the details LongOdds and let's hope 13 is lucky!

it is interesting the Company has managed to secure the stock code 13 which is considered a lucky number in China. Some smaller investors are likely to buy into the Company simply to have that stock code in their portfolio! As far as I can tell 13 is the only number in the double digit range that has never been used.

I've noticed there have been euro denominated adr's trading in Frankfurt since:-
DB:H7T1 (since June 2016)
DB:H7T2 (since May 2019)

I've seen this for a couple of years when I look at simply wall street - they appear to be Euro denominated adr's

tx for posting saigonsally - interesting that these and others still go on about Li ka-shing

Volume 1,021,887
Avg. volume 247,255

I hope the instis who took part on the IPO @ circa $25.82 don't dump the stock next week when it starts trading just to make a fast buck. We need long term holders, not opportunistic IPO traders.

surprising price but at least it's up 11% since the announcement - the people taking part in the placing have got a huge bargain in my opinion

hope so, I want to be back at $40

A good point/question re the confirmatory study jatw; does that mean AZ cannot launch Orpathys in China until that is completed and if so I wonder how long that will take.

It's great to see AZ announcing the approval of Orpathys aka Savolitinib via RNS today

https://otp.tools.investis.com/clients/uk/astrazeneca/rns/regulatory-story.aspx?cid=1343&newsid=1485837

Trinity Delta have posted an updated Research note

https://www.trinitydelta.org/wp-content/uploads/2021/06/HCM-Lighthouse-210621.pdf

Wonderful! The first ever approval for Savolitinib!